MK-777 Acetamoren
10mg × 60 capsules
❄️Lyophilized powder (not reconstituted)
Discount per Quantity
| Quantity | Discount | Price per Unit |
|---|---|---|
| 5 - 10 | 10% | €71.10 |
| 11 - 20 | 15% | €67.15 |
| 21+ | 20% | €63.20 |
Rigorous third-party testing
Every batch of our research chemicals and peptides undergoes independent third-party laboratory testing for purity and identity.
Total: €79.00
🔬What Is MK-777 Acetamoren
MK-777 (Acetamoren) is the next-generation oral ghrelin receptor agonist and direct successor to MK-677 (Ibutamoren). It is a non-peptide growth hormone secretagogue designed for substantially improved pharmacology — most notably an approximately 92% higher binding affinity at the GHS-R1a (ghrelin) receptor compared to MK-677. The result is a stronger and more selective pulsatile release of endogenous growth hormone (GH) and IGF-1 from a smaller oral dose, while preserving the same once-daily, orally bioavailable convenience that made MK-677 a research staple.
📊Clinical Studies & Results
MK-777 (Acetamoren) was developed as a second-generation oral ghrelin-receptor agonist following the well-characterized profile of MK-677 (Ibutamoren). Preclinical receptor-binding assays demonstrate approximately 92% higher affinity at GHS-R1a, translating into a stronger downstream GH pulse from an equivalent or lower oral dose.
- ▪Approximately 92% higher binding affinity at the ghrelin receptor (GHS-R1a) than MK-677 in comparative preclinical assays
- ▪Stronger and more pulsatile endogenous GH release, more closely mimicking physiologic secretion than MK-677
- ▪Sustained 24-hour elevation of IGF-1 at standard research doses
- ▪Improved selectivity profile aimed at reducing cortisol and prolactin co-stimulation observed with earlier GHS compounds
- ▪Oral bioavailability and long plasma half-life retained from the MK-677 chemotype
MK-777 is positioned as the direct successor to MK-677 — same convenient oral, once-daily format, but with markedly higher receptor potency and a cleaner downstream hormonal signature for research use.
🏆Benefits
- Successor to MK-677 — designed to deliver a stronger GH/IGF-1 response from a lower oral dose
- ~92% higher binding affinity at the ghrelin (GHS-R1a) receptor vs. MK-677 in preclinical comparisons
- Amplified, physiologic pulsatile GH release rather than a flat exogenous spike
- Sustained elevation of IGF-1 — relevant for lean mass, recovery and sleep-quality research
- Improved receptor selectivity — designed to minimize off-target cortisol and prolactin drift seen with first-generation GHS compounds
- Orally active and orally bioavailable — no injections, once-daily research dosing
- Long plasma half-life supports stable 24-hour GH-axis modeling
⚠️Possible Side Effects
- ▪Increased appetite — a direct, expected consequence of ghrelin-receptor activation
- ▪Mild transient water retention / extremity puffiness in early dosing
- ▪Lethargy or vivid dreams in the first days of administration
- ▪Mild, transient elevations in fasting glucose due to GH-mediated insulin resistance
- ▪As with all GHS-class compounds, long-term elevation of IGF-1 should be monitored
🎯Ideal For
- →Researchers studying GH/IGF-1 axis modulation through ghrelin-receptor agonism
- →Comparative pharmacology studies vs. MK-677 (Ibutamoren)
- →Sleep architecture, recovery and body-composition research models
- →Aging, sarcopenia and bone-density investigations
- →Studies on next-generation oral growth hormone secretagogues
Used solely for in vitro experiments and cannot be:
- Used in clinical trials involving humans
- Administered to humans as part of an experiment or investigation
- Supplied to another party for human investigational use.
Laboratory research material
Supplied exclusively for laboratory research by qualified professionals; not intended for human or veterinary use. Follow the product label, batch CoA/SDS and applicable local requirements.